RMD Share Price History
11 May, 2021
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its masks.
07 May, 2021
It looks like ResMed Inc. ( NYSE:RMD ) is about to go ex-dividend in the next four days. You can purchase shares before...
06 May, 2021
How far off is ResMed Inc. ( NYSE:RMD ) from its intrinsic value? Using the most recent financial data, we'll take a...
03 May, 2021
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- Bone Health Technologies, a leading innovator of technologies for improving bone health, announces today the close of its $2.5 million funding round and the appointment of three board members: Karen Drexler, MBA, Nancy Lynch, MD, MBA and Sam Goldberger, MD, MBA. “Our mission is to provide an effective and safe treatment for the more than 40 million Americans with low bone density - this capital and the expertise we are bringing to bear is exactly what we need to complete our pivotal trial and bring this important innovation to market,” shared Laura Yecies, CEO of Bone Health Technologies (BHT). “We have been involved with Bone Health Technologies since the early proof of concept stage and are thrilled to lead this investment round - the unmet need and hence the business opportunity is enormous” said John Osborne, Managing Partner, Good Growth Capital. Good Growth Capital led the oversubscribed funding round which includes investments by Astia Angels, Ambit Health Ventures, Portfolia Femtech Fund, IT-Farm, Golden Seeds, Berkeley Angel Network, the Band of Angels, Reno Seed Fund as well as prominent individual Angel Investors. A founding member of Astia Angels, Karen Drexler now joins the Bone Health Technologies board in addition to her board positions at ResMed (RSMD:NYSE), Outset Medical (Nasdaq:OM), Tivic Health and VIDA Diagnostics. She brings extensive commercial and technical experience to the board team from a variety of health and medical focused organizations. Sam Goldberger, MD, MBA brings significant medical expertise to the BHT board. Dr. Goldberger is Co-Founder and Managing Partner of Ambit Health Ventures and has over 28 years of surgical experience. Nancy Lynch, MD, MBA is also joining the board. Dr. Lynch has more than 25 years of experience in the clinical and business elements of orthopedics. She is a Board-certified, fellowship-trained orthopedic surgeon and a fellow of the American Academy of Orthopedic Surgeons and has served as Chief Medical Officer of and consultant to several medical device companies. The round and board appointments add to a successful year for BHT. It recently appointed CEO Laura Yecies and was granted Breakthrough Device Designation by the FDA for OsteoBoost, the first vibration belt specifically designed for the prevention of osteoporosis. At the 2021 One Harvard New Venture Competition, Bone Health Technologies was awarded both the One Harvard New Venture Competition Grand Prize Winner and Northern California Crowd Favorite titles. Osteoboost is based on NASA research which proved that medical stimulation of bones through vibration would improve bone health in astronauts. Studies have shown that one 30-minute treatment with OsteoBoost reduced bone loss activity in all study participants. For more information on the CEO appointment or Bone Health Technologies and OsteoBoost please visit: http://www.bonehealthtech.com/ ABOUT BONE HEALTH TECHNOLOGIES:Bone Health Technologies is a San Francisco based company that applies science and medical expertise to create better health outcomes for women and men at risk of developing osteoporosis and the associated bone fractures. Initially created in the med-tech incubator TheraNova, Bone Health Technologies is poised to become the new standard of care in treating both osteoporosis and osteopenia (the precursor to osteoporosis). Visit www.bonehealthtech.com for more information. CONTACT: MEDIA CONTACT: Michelle Kafka 407-603-5716 Michelle@kafkamediagroup.com
30 Apr, 2021
Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.
RMD earnings call for the period ending March 31, 2021.
29 Apr, 2021
ResMed (RMD) delivered earnings and revenue surprises of 6.56% and -2.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- Year-over-year operating profit up 3%, non-GAAP operating profit up 2% Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced results for its quarter ended March 31, 2021. Third Quarter 2021 HighlightsAll comparisons are to the prior year period Revenue was comparable at $768.8 million; down 3% on a constant currency basisGAAP gross margin of 58.2%; non-GAAP gross margin contracted 40 bps to 59.6%Net operating profit increased 3%; non-GAAP operating profit up 2%GAAP diluted earnings (loss) per share of $(0.54); non-GAAP diluted earnings per share of $1.30 “Our March 2021 quarter results reflect the ongoing recovery of core patient flow across our business, while we anniversary the $35 million of incremental COVID-19 revenue in the same quarter last year. Excluding the COVID-19 revenue from the March 2020 quarter, we achieved positive revenue growth on both a headline and constant currency basis,” said Mick Farrell, ResMed CEO. “Our global team is supporting patients and all of our customers as the most recent waves of COVID-19 cases impact parts of Europe, Asia, and South America. I am extremely proud of our ResMed team as they innovate with new digital pathways for patients to be diagnosed and treated for their sleep apnea, COPD, asthma, and out-of-hospital needs. "During the quarter we also made substantial progress toward resolving our long-running dispute with the Australian Tax Office. Although we do not have a final agreement, we have taken a reserve of $255 million, reflecting our estimate of the net impact of a potential settlement. Our next steps are to agree on the final terms of a resolution giving us clarity for the future. "Going forward, we see accelerated awareness of the importance of respiratory health, growing adoption of digital health, and an increased focus on the importance of healthcare delivered at home. We are confident in accelerated growth in patient flow, and ongoing progress toward our goal of improving 250 million lives in out-of-hospital healthcare in 2025.” Financial Results and Operating MetricsUnaudited; $ in millions, except for per share amounts Three Months Ended March 31,2021 March 31,2020 % Change Constant Currency (A) Revenue$768.8 $769.5 (0)% (3)% Gross margin (B) 58.2 % 58.4% (0) Non-GAAP gross margin (B) 59.6 % 60.0% (1) Selling, general, and administrative expenses 160.4 172.4 (7) (11) Research and development expenses 55.9 51.4 9 3 Income from operations 223.4 217.5 3 Non-GAAP income from operations (B) 241.8 237.9 2 Net income (loss) (78.5) 163.1 (148) Non-GAAP net income (B) 190.4 187.9 1 Diluted earnings (loss) per share$(0.54) $1.12 (148) Non-GAAP diluted earnings per share (B)$1.30 $1.29 1 Nine Months Ended March 31,2021 March 31,2020 % Change Constant Currency (A) Revenue$2,320.7 $2,186.7 6 % 4 % Gross margin (B) 58.1 % 58.0% 0 Non-GAAP gross margin (B) 59.8 % 59.8% - Selling, general, and administrative expenses 488.9 511.3 (4) (7) Research and development expenses 165.4 149.4 11 7 Income from operations 662.0 586.4 13 Non-GAAP income from operations (B) 733.4 647.4 13 Net income 279.4 443.8 (37) Non-GAAP net income (B) 582.2 499.5 17 Diluted earnings per share$1.91 $3.05 (37) Non-GAAP diluted earnings per share (B)$3.98 $3.43 16 (A) In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.(B) See the reconciliation of non-GAAP financial measures in the table at the end of the press release. Discussion of Third Quarter ResultsAll comparisons are to the prior year period unless otherwise noted During the March quarter, we derived no incremental revenue from COVID-19 related demand whereas our prior year quarter included incremental revenue in the order of $35 million. Excluding the impact of the incremental COVID-19 related revenue from the prior year quarter, revenue increased by 1 percent on a constant currency basis.Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 2 percent, driven by strong sales across our mask product portfolio, partially offset by lower device sales, including decreased demand for our ventilators due to COVID-19.Revenue in Europe, Asia, and other markets declined by 13 percent on a constant currency basis, primarily driven by lower device sales, including decreased demand for our ventilators due to COVID-19, and flat sales in our mask product portfolio.Software as a Service revenue increased by 5 percent, due to continued growth in resupply service offerings and stabilizing patient flow in out-of-hospital care settings.Gross margin decreased by 20 basis points and non-GAAP gross margin decreased by 40 basis points, mainly due to additional manufacturing costs associated with the transition to our new Singapore site during the quarter, higher freight costs and geographic mix changes.Selling, general, and administrative expenses decreased by 11 percent on a constant currency basis. SG&A expenses improved to 20.9 percent of revenue in the quarter, compared with 22.4 percent in the same period of the prior year. These changes in SG&A expenses were mainly due to savings in travel and other cost management as a result of the COVID-19 pandemic.Income from operations increased by 3 percent and non-GAAP income from operations increased by 2 percent.Our income tax expense was impacted by the recognition of a $254.8 million reserve in relation to our ongoing dispute with the Australian Tax Office covering tax years 2009-2018.Net loss for the quarter was $78.5 million and diluted loss per share was $0.54, predominantly due to the additional income tax reserve of $254.8 million. Non-GAAP net income grew by 1 percent to $190.4 million and non-GAAP diluted earnings per share grew by 1 percent to $1.30.Cash flow from operations for the quarter was $196.3 million, compared to net loss in the current quarter of $78.5 million and non-GAAP net income of $190.4 million. During the quarter we paid $56.8 million in dividends. Dividend programThe ResMed board of directors today declared a quarterly cash dividend of $0.39 per share. The dividend will have a record date of May 13, 2021, payable on June 17, 2021. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 12, 2021, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 12, 2021, through May 13, 2021, inclusive. Webcast detailsResMed will discuss its third quarter fiscal year 2021 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2021 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 800-585-8367 (U.S.) or +1 416-621-4642 (outside U.S.) and entering the passcode 7757454. The telephone replay will be available until May 13, 2021. About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed. Safe harbor statementStatements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements. RESMED INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations(Unaudited; $ in thousands, except for per share amounts) Three Months Ended Nine Months Ended March 31,2021 March 31,2020 March 31,2021 March 31,2020 Net revenue$768,767 $769,455 $2,320,722 $2,186,669 Cost of sales 310,585 307,657 933,021 880,633 Amortization of acquired intangibles (1) 10,924 12,136 34,066 37,623 Restructuring - cost of sales (1) - - 5,232 - Total cost of sales$321,509 $319,793 $972,319 $918,256 Gross profit$447,258 $449,662 $1,348,403 $1,268,413 Selling, general, and administrative 160,446 172,441 488,904 511,304 Research and development 55,941 51,449 165,409 149,425 Amortization of acquired intangibles (1) 7,445 8,272 23,377 21,872 Restructuring - operating expenses (1) - - 8,673 - Litigation settlement expenses (1) - - - (600) Total operating expenses$223,832 $232,162 $686,363 $682,001 Income from operations 223,426 217,500 662,040 586,412 Other income (expenses), net: Interest income (expense), net$(5,823) $(9,852) $(18,341) $(30,414) Loss attributable to equity method investments (4,969) (5,295) (9,895) (19,082) Other, net 5,371 (10,698) 10,647 (15,922) Total other income (expenses), net (5,421) (25,845) (17,589) (65,418) Income before income taxes$218,005 $191,655 $644,451 $520,994 Income taxes 296,486 28,518 365,046 77,155 Net income (loss)$(78,481) $163,137 $279,405 $443,839 Basic earnings (loss) per share$(0.54) $1.13 $1.92 $3.08 Diluted earnings (loss) per share$(0.54) $1.12 $1.91 $3.05 Non-GAAP diluted earnings (loss) per share (1)$1.30 $1.29 $3.98 $3.43 Basic shares outstanding 145,513 144,638 145,217 144,112 Diluted shares outstanding 145,513 145,680 146,394 145,490 (1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release. RESMED INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets(Unaudited; $ in thousands) March 31,2021 June 30,2020 ASSETS Current assets: Cash and cash equivalents$230,635 $463,156 Accounts receivable, net 525,014 474,643 Inventories 484,061 416,915 Prepayments and other current assets 226,440 168,745 Total current assets$1,466,150 $1,523,459 Non-current assets: Property, plant and equipment, net$455,106 $417,335 Operating lease right-of-use assets 128,755 118,348 Goodwill and other intangibles, net 2,335,550 2,338,492 Deferred income taxes and other non-current assets 200,163 189,742 Total non-current assets$3,119,574 $3,063,917 Total assets$4,585,724 $4,587,376 LIABILITIES AND STOCKHOLDERS’ EQUITY: Current liabilities: Accounts payable$117,222 $135,786 Accrued expenses 304,693 270,353 Operating lease liabilities, current 22,499 21,263 Deferred revenue 105,342 98,617 Income taxes payable 314,795 64,755 Short-term debt 11,990 11,987 Total current liabilities$876,541 $602,761 Non-current liabilities: Deferred revenue$86,898 $87,307 Deferred income taxes 12,474 13,011 Operating lease liabilities, non-current 115,266 101,880 Other long-term liabilities 6,067 8,347 Long-term debt 719,046 1,164,133 Long-term income taxes payable 60,198 112,910 Total non-current liabilities$999,949 $1,487,588 Total liabilities$1,876,490 $2,090,349 STOCKHOLDERS’ EQUITY: Common stock$582 $580 Additional paid-in capital 1,586,545 1,570,694 Retained earnings 2,941,336 2,832,991 Treasury stock (1,623,256) (1,623,256) Accumulated other comprehensive income (195,973) (283,982) Total stockholders’ equity$2,709,234 $2,497,027 Total liabilities and stockholders' equity$4,585,724 $4,587,376 RESMED INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows(Unaudited; $ in thousands) Nine Months Ended March 31,2021 March 31,2020 Cash flows from operating activities: Net income$279,405 $443,839 Adjustment to reconcile net income to cash provided by operating activities: Depreciation and amortization 120,034 116,341 Amortization of right-of-use assets 25,805 19,524 Stock-based compensation costs 47,032 41,421 Loss attributable to equity method investments 9,895 19,082 (Gain) loss on equity investment (9,442) 14,519 Restructuring expenses 8,673 - Changes in fair value of business combination contingent consideration - (7) Changes in operating assets and liabilities: Accounts receivable, net (39,899) (34,140) Inventories, net (48,393) (22,564) Prepaid expenses, net deferred income taxes and other current assets (41,036) (68,724) Accounts payable, accrued expenses and other 158,119 (57,301) Net cash provided by operating activities$510,193 $471,990 Cash flows from investing activities: Purchases of property, plant and equipment (74,805) (77,360) Patent registration costs (11,149) (7,391) Business acquisitions, net of cash acquired (30,704) (27,910) Purchases of investments (20,038) (31,616) Proceeds / (Payments) on maturity of foreign currency contracts 26,306 (32,177) Net cash used in investing activities$(110,390) $(176,454) Cash flows from financing activities: Proceeds from issuance of common stock, net 18,759 26,112 Taxes paid related to net share settlement of equity awards (49,938) (45,106) Payment of business combination contingent consideration (3,500) (302) Proceeds from borrowings, net of borrowing costs 90,000 990,000 Repayment of borrowings (536,000) (883,012) Dividends paid (169,917) (168,610) Net cash used in financing activities$(650,596) $(80,918) Effect of exchange rate changes on cash$18,272 $(8,885) Net increase / (decrease) in cash and cash equivalents (232,521) 205,733 Cash and cash equivalents at beginning of period 463,156 147,128 Cash and cash equivalents at end of period$230,635 $352,861 RESMED INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures(Unaudited; $ in thousands, except for per share amounts) The measures “non-GAAP gross profit” and “non-GAAP gross margin” excludes amortization expense from acquired intangibles related to cost of sales and are reconciled below: Three Months Ended Nine Months Ended March 31,2021 March 31,2020 March 31,2021 March 31,2020 Revenue$768,767 $769,455 $2,320,722 $2,186,669 Add back: Deferred revenue fair value adjustment (A) - - - 2,102 Non-GAAP revenue$768,767 $769,455 $2,320,722 $2,188,771 GAAP cost of sales$321,509 $319,793 $972,319 $918,256 Less: Amortization of acquired intangibles (A) (10,924) (12,136) (34,066) (37,623) Less: Restructuring - cost of sales (A) - - (5,232) - Non-GAAP cost of sales$310,585 $307,657 $933,021 $880,633 GAAP gross profit$447,258 $449,662 $1,348,403 $1,268,413 GAAP gross margin 58.2 % 58.4 % 58.1 % 58.0 %Non-GAAP gross profit$458,182 $461,798 $1,387,701 $1,308,138 Non-GAAP gross margin 59.6 % 60.0 % 59.8 % 59.8 % The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below: Three Months Ended Nine Months Ended March 31,2021 March 31,2020 March 31,2021 March 31,2020 GAAP income from operations$223,426 $217,500 $662,040 $586,412 Amortization of acquired intangibles - cost of sales (A) 10,924 12,136 34,066 37,623 Amortization of acquired intangibles - operating expenses (A) 7,445 8,272 23,377 21,872 Restructuring - cost of sales (A) - - 5,232 - Restructuring - operating expenses (A) - - 8,673 - Deferred revenue fair value adjustment (A) - - - 2,102 Litigation settlement expenses (A) - - - (600)Non-GAAP income from operations$241,795 $237,908 $733,388 $647,409 RESMED INC. AND SUBSIDIARIES Reconciliation of Non-GAAP Financial Measures(Unaudited; $ in thousands, except for per share amounts) The measures "non-GAAP net income" and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below: Three Months Ended Nine Months Ended March 31,2021 March 31,2020 March 31,2021 March 31,2020 GAAP net income (loss)$(78,481) $163,137 $279,405 $443,839 Amortization of acquired intangibles - cost of sales, net of tax (A) 8,395 9,287 26,136 28,765 Amortization of acquired intangibles - operating expenses, net of tax (A) 5,721 6,330 17,936 16,723 Reserve for disputed tax position (A) 254,776 - 254,776 - Restructuring - cost of sales, net of tax (A) - - 4,663 - Restructuring - operating expenses, net of tax (A) - - 7,730 - (Gain) loss on equity investments (A) - - (8,476) - Fair value impairment of investment (A) - 9,100 - 9,100 Deferred revenue fair value adjustment, net of tax (A) - - - 1,610 Litigation settlement expenses, net of tax (A) - - - (528) Non-GAAP net income (A)$190,411 $187,854 $582,170 $499,509 GAAP diluted shares outstanding 145,513 145,680 146,394 145,490 Anti-dilutive shares excluded from GAAP 858 - - - Non-GAAP diluted shares outstanding 146,371 145,680 146,394 145,490 GAAP diluted earnings (loss) per share$(0.54) $1.12 $1.91 $3.05 Non-GAAP diluted earnings per share (A)$1.30 $1.29 $3.98 $3.43 (A) ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses, deferred revenue fair value adjustment, litigation settlement expenses, the (gain) loss on equity investments and the fair value impairment of investment from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. RESMED INC. AND SUBSIDIARIES Revenue by Product and Region (Unaudited; $ in millions, except for per share amounts) Three Months Ended March 31, 2021 (A) March 31, 2020 (A) % Change Constant Currency (B) U.S., Canada and Latin America Devices$192.9 $196.5 (2)% Masks and other 210.0 197.1 7 Total Sleep and Respiratory Care$402.9 $393.5 2 Software as a Service 93.8 89.6 5 Total$496.7 $483.1 3 Combined Europe, Asia and other markets Devices$172.8 $195.0 (11)% (18)% Masks and other 99.2 91.3 9 0 Total Sleep and Respiratory Care$272.1 $286.3 (5) (13) Global revenue Devices$365.7 $391.5 (7)% (10)% Masks and other 309.2 288.4 7 4 Total Sleep and Respiratory Care$674.9 $679.9 (1) (4) Software as a Service 93.8 89.6 5 5 Total$768.8 $769.5 (0) (3) Nine Months Ended March 31, 2021 (A) March 31, 2020 (A) % Change Constant Currency (B) U.S., Canada and Latin America Devices$595.3 $586.9 1 % Masks and other 637.5 584.9 9 Total Sleep and Respiratory Care$1,232.8 $1,171.8 5 Software as a Service 277.8 263.2 6 Total$1,510.6 $1,435.0 5 Combined Europe, Asia and other markets Devices$536.9 $509.3 5 % (1)% Masks and other 273.3 242.4 13 6 Total Sleep and Respiratory Care$810.1 $751.7 8 2 Global revenue Devices$1,132.1 $1,096.2 3 % 0 % Masks and other 910.8 827.3 10 8 Total Sleep and Respiratory Care$2,042.9 $1,923.5 6 4 Software as a Service 277.8 263.2 6 6 Total$2,320.7 $2,186.7 6 4 (A) Totals and subtotals may not add due to rounding.(B) In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. For investorsFor mediaAmy WakehamJayme Rubenstein+1 858-836-5000+1 firstname.lastname@example.org@resmed.com
28 Apr, 2021
The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
27 Apr, 2021
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Wednesday, May 5, 2021, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via video webcast. More information about this event, including access to the live webcast, may be accessed by visiting http://investor.resmed.com. The webcast replay will be available to Macquarie clients approximately 24 hours after the live webcast ends and will be accessible through May 26, 2021. About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed. For investors For mediaAmy Wakeham Jayme Rubenstein+1 858.836.5000 +1 email@example.com firstname.lastname@example.org
23 Apr, 2021
Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.
22 Apr, 2021
In this article you are going to find out whether hedge funds think ResMed Inc. (NYSE:RMD) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
21 Apr, 2021
When investors talk about value stocks, they are usually speaking of companies with cheap shares. Vertex Pharmaceuticals (NASDAQ: VRTX), Align Technology (NASDAQ: ALGN), and ResMed (NYSE: RMD) each have a great track record and financial performance that easily justifies its current valuation. Breaking down the numbers, they could be the best value stocks in the healthcare sector right now.
14 Apr, 2021
With big growth trending for CPAP machines and related products, the two biggest names in sleep apnea are expected to prosper this year.
09 Apr, 2021
In this episode of Industry Focus: Wildcard, join Motley Fool contributor Brian Feroldi and host Emily Flippen as they talk about three companies trying to treat sleep apnea: ResMed (NYSE: RMD), Inspire Medical (NYSE: INSP), and Vivos Therapeutics (NASDAQ: VVOS). To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Today is Wednesday, March 24th, and I am your host, Emily Flippen.
08 Apr, 2021
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2021 on Thursday, April 29, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast. Earnings webcast details: • Location: http://investor.resmed.com • Date: Thursday, April 29, 2021 • Time: 1:30 p.m. PDT / 4:30 p.m. EDT • International: London, Thursday, April 29, 9:30 p.m. BST Sydney, Friday, April 30, 6:30 a.m. AEST Please note that ResMed does not use outside phone lines to access the earnings call.A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from April 29 until May 13 at: U.S.: +1 800.585.8367International: +1 416.621.4642Conference ID: 7757454 About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed. For investors Amy Wakeham +1 858.836.5000 email@example.com For mediaJayme Rubenstein+1 firstname.lastname@example.org
16 Mar, 2021
ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer and Brett Sandercock, chief financial officer, will participate in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on Tuesday, March 23, 2021, beginning at approximately 4:15 p.m. (Eastern Daylight Time) via video webcast.
15 Mar, 2021
New Survey Shows Stress Over the Past Year Is Negatively Impacting the Quality of Sleep for Half of Americans
ResMed's 2021 U.S. Consumer Sleep Survey reveals how many Americans have symptoms of a common sleep disorder, but aren't concerned about them.
MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, announced the appointment of Kristie Burns to the position of Senior Vice President of Marketing & Clinical Affairs, effective March 22, 2021. Ms. Burns will succeed Darren Wennen, who was promoted from Vice President of Marketing & Clinical Affairs to Senior Vice President of Commercial Operations. “With over 25 years in the healthcare industry, Kristie brings a wealth of commercial leadership experience in the treatment of chronic conditions with connected at-home solutions,” said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. “Having developed markets with underdiagnosed/undertreated conditions at both ResMed and Cala Health, I expect her to help strengthen our market penetration efforts which will lead to more patients getting the treatment they deserve. I am very pleased to welcome Kristie to Tactile Medical and look forward to her contributions as a member of our executive leadership team.” Prior to joining Tactile Medical, Ms. Burns was the Chief Marketing Officer at Cala Health, Inc., a privately-held bioelectronic medicine company developing wearable neuromodulation therapies for chronic disease. At Cala Health, she organized the company’s commercial functions and managed the U.S. commercial introduction of its lead product. Ms. Burns previously worked for 13 years at ResMed Inc. (NYSE: RMD) a global leader in digital health and cloud-connected medical devices focused on sleep apnea and other chronic diseases. She joined ResMed as a Market Development Manager in 2003 and subsequently held multiple positions of increasing responsibility culminating as Vice President of Solutions Marketing for ResMed Americas. She began her career with a privately-held cardiology consulting practice that was subsequently acquired by GE Medical Systems. “I’m very pleased to join Dan and the team to fuel healthy growth and the expansion of Tactile Medical,” said Ms. Burns. “Moreover, I’m excited to continue advancing the impact of at-home therapies for people living with chronic conditions.” About Tactile Medical Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency. Tactile Medical’s Mission is to help people suffering from chronic diseases live better and care for themselves at home. The Company’s unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinicians. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions. Legal Notice Regarding Forward-Looking Statements: This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the impacts of the COVID-19 pandemic on the Company’s business, financial condition and results of operations; the course of the COVID-19 pandemic and its impact on general economic, business and market conditions; the Company’s inability to execute on its plans to respond to the COVID-19 pandemic; the adequacy of the Company’s liquidity to pursue its business objectives; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives, including prior to identifying a successor; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. CONTACT: Investor Inquiries: Mike Piccinino, CFA Managing Director Westwicke Partners email@example.com